Molecular Sensing, Inc. (MSI) is commercializing Back-Scattering Interferometry (BSI), the world’s first label-free, conformation-sensitive, free-solution assay technology for biophysical characterization of small molecule interactions with complex drug targets. This includes crude membrane protein preparations and other biochemically intractabletarget binding assays in native-like, free-solution environments — no tags or tethering